Melt Pharmaceuticals Reports First Patient Dosed In Phase 3 Program Of Its MELT-300, For Needle- And Opioid-Free Sedation In Patients Undergoing Cataract Surgery; Topline Readout Expected In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Melt Pharmaceuticals has dosed the first patient in its Phase 3 trial for MELT-300, a non-IV, non-opioid sedation tablet for cataract surgery. The trial involves 528 patients and uses Catalent's Zydis® technology. Results are expected in Q4 2024.
June 06, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalent Inc. is providing its Zydis® fast-dissolving technology for Melt Pharmaceuticals' Phase 3 trial of MELT-300. This collaboration highlights Catalent's role in innovative drug delivery solutions.
Catalent's involvement in the Phase 3 trial of MELT-300 showcases its advanced drug delivery technology, which could enhance its reputation and lead to more partnerships, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Melt Pharmaceuticals, associated with HROW, has initiated a Phase 3 trial for MELT-300, a non-IV, non-opioid sedation tablet for cataract surgery. Results are expected in Q4 2024.
The initiation of a Phase 3 trial is a significant milestone for Melt Pharmaceuticals and its associated companies, including HROW. Positive results could lead to FDA approval and commercialization, potentially boosting HROW's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80